Freestone Grove Partners LP
Position in SUPN — Supernus Pharmaceuticals, Inc.
CIK 2007591
San Francisco, CA
Position in SUPN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$14,715,670
-$18,434,109 QoQ
Shares Held
316,398
-50.7% QoQ
Ownership
0.544%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
#37
of 331 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SUPN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Freestone Grove Partners LP holds $100,700,353 across 12 Drug Manufacturers - Specialty & Generic names. SUPN ranks #3 (14.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ELAN |
Elanco Animal Health Inc
|
2,170,681 | $53,420,459 | |
| 2 | TEVA |
Teva Pharmaceutical Industries Ltd
|
604,053 | $20,465,315 | |
| 3 | SUPN |
Supernus Pharmaceuticals, Inc.
This page
|
316,398 | $14,715,670 | |
| 4 | ANIP |
Ani Pharmaceuticals Inc
|
101,332 | $8,388,262 | |
| 5 | COLL |
Collegium Pharmaceutical, Inc
|
44,493 | $1,610,646 | |
| 6 | PBH |
Prestige Consumer Healthcare Inc.
|
18,079 | $854,594 | |
| 7 | UTHR |
UNITED THERAPEUTICS Corp
|
1,207 | $653,988 | |
| 8 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
4,615 | $295,129 |
All Filings in SUPN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $14,715,670 | 316,398 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $33,149,779 | 641,319 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $9,757,004 | 196,318 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||